US DEA May Change the Game for Cannabis Investors
Picture this: Overnight, shares in cannabis‑based health companies have more than doubled, sparking a buying frenzy that feels less like a market move and more like a midnight snack drive‑by.
What’s Fueling the Frenzy?
- The U.S. Drug Enforcement Administration (DEA) is moving to reclassify marijuana from a Schedule I (the same tier as heroin and LSD) to Schedule III, which includes steroids, codeine, and testosterone.
- Under a Schedule III designation, cannabis would become regulated like prescription drugs, signalling that its therapeutic use could soon be legally protected.
- Investors have ripened their appetite for companies that grow, process, or market medical cannabis.
Stock Sizzle Snapshot
- Canopy Growth Corp’s shares surged 80.02% in just 24 hours.
- Aurora Cannabis Inc posted a 46.24% spike one day, followed by a staggering 113.32% month‑on‑month rise.
- These numbers aren’t just digits—they’re the headline of a story that’s catching eyes across North America and Europe.
Why Investors Are Buzzing
Oskar Barner Bernhardtsen, Investment Strategist at Saxo, offers a quick breakdown:
“After the DEA’s policy shift, energy surged overnight. Coupled with Germany’s legalization of recreational cannabis and Senate Majority Leader Chuck Schumer’s endorsement of the SAFER Banking Act, the cannabis sector’s share prices leapt like a springboard.”
“Some of our cannabis picks jumped as much as 80% overnight—proof that confidence is high and growth potential is real.”
“But remember the historical volatility and regulatory maze.”
What’s Next?
With the U.S. and European markets edging toward broader legalization, the therapeutic cannabis industry could experience a double‑whammy of growth: easier access plus a wider customer base. For investors, it’s a thrilling—yet risky—playtime.
Stay in the Loop
Want real‑time updates on how prices wobble? Subscribe now and keep the news on your device.
